Association of Plasma Claudin-5 with Age and Alzheimer Disease
International Journal of Molecular Sciences · 24.01.2024 · 25 (3) · 1419
DOI: 10.3390/ijms25031419 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.01.2024. Verfasst von Keisuke Tachibana und 6 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmaceutical Sciences, Osaka University, Suita 565-0871, Osaka, Japan. Hauptthemen laut MEDLINE: Alzheimer Disease, Claudin-5, Cognitive Dysfunction. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development, Japan Society for the Promotion of Science, JSPS KAKENHI.
Themen: Demenz
Abstract (Originalsprache)
The blood–brain barrier (BBB) plays pivotal roles in synaptic and neuronal functioning by sealing the space between adjacent microvascular endothelial cells. BBB breakdown is present in patients with mild cognitive impairment (MCI) or Alzheimer disease (AD). Claudin-5 (CLDN-5) is a tetra-spanning protein essential for sealing the intercellular space between adjacent endothelial cells in the BBB. In this study, we developed a blood-based assay for CLDN-5 and investigated its diagnostic utility using 100 cognitively normal (control) subjects, 100 patients with MCI, and 100 patients with AD. Plasma CLDN-5 levels were increased in patients with AD (3.08 ng/mL) compared with controls (2.77 ng/mL). Plasma levels of phosphorylated tau (pTau181), a biomarker of pathological tau, were elevated in patients with MCI or AD (2.86 and 4.20 pg/mL, respectively) compared with control subjects (1.81 pg/mL). In patients with MCI or AD, plasma levels of CLDN-5—but not pTau181—decreased with age, suggesting some age-dependent BBB changes in MCI and AD. These findings suggest that plasma CLDN-5 may a potential biochemical marker for the diagnosis of AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Graduate School of Pharmaceutical Sciences, Osaka University, Suita 565-0871, Osaka, Japan.
- Graduate School of Medicine, Osaka University, Suita 565-0871, Osaka, Japan.
- Department of Aging Neurobiology, Center for Development of Advanced Medicine for Dementia, National Center for Geriatrics and Gerontology, Obu 474-8511, Aichi, Japan.
- Department of Bioresources, Medical Genome Center, National Center of Neurology and Psychiatry, Kodaira 187-8551, Tokyo, Japan.
- Department of Clinical and Experimental Neuroimaging, National Center for Geriatrics and Gerontology, Obu 474-8511, Aichi, Japan.
- Proteo-Science Center, Ehime University, Matsuyama 790-8577, Ehime, Japan.
ORCID-Profile: Keisuke Tachibana, Ryuichi Hirayama, Hiroyuki Takeda
Förderung
- Japan Agency for Medical Research and Development
- Japan Society for the Promotion of Science
- JSPS KAKENHI
Zitieren
APA
Tachibana, K., Hirayama, R., Sato, N., Hattori, K., Kato, T., Takeda, H., & Kondoh, M. (2024). Association of Plasma Claudin-5 with Age and Alzheimer Disease. International Journal of Molecular Sciences, 25(3), 1419. https://doi.org/10.3390/ijms25031419
Vancouver
Tachibana K, Hirayama R, Sato N, Hattori K, Kato T, Takeda H, et al. Association of Plasma Claudin-5 with Age and Alzheimer Disease. International Journal of Molecular Sciences. 2024;25(3):1419. doi:10.3390/ijms25031419
BibTeX
@article{Tachibana2024,
author = {Tachibana, Keisuke and Hirayama, Ryuichi and Sato, Naoyuki and Hattori, Kotaro and Kato, Takashi and Takeda, Hiroyuki and Kondoh, Masuo},
title = {Association of Plasma Claudin-5 with Age and Alzheimer Disease},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {3},
pages = {1419},
doi = {10.3390/ijms25031419}
}
EUVIMED